This article was originally published in The Gray Sheet
Executive SummaryCompany forecasts during its Dec. 11 analyst day in New York that sales of the Sapien transcatheter heart valve will reach $75 million-$95 million in 2009. Edwards also reaffirms it is on track to start U.S. clinical trials by the end of next year for its next-generation Sapien XT valve. The firm presented early European data on transfemoral delivery of Sapien at the Transcatheter Cardiovascular Therapeutics meeting in October (1"The Gray Sheet" Oct. 20, 2008, p. 16). Edwards' total heart valve therapy business is anticipated to grow 14%-16% in 2009 to $640 million-$670 million. Corporate sales are forecast at $1.24 billion-$1.3 billion
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.